Skip to main content

3 Result(s)

within Dana N. Raugi Remove this filter

and

  1. Article

    Open Access

    Resource and infrastructure challenges on the RESIST-2 Trial: an implementation study of drug resistance genotype-based algorithmic ART switches in HIV-2-infected adults in Senegal

    Second-line treatment of HIV-2 in resource-limited settings (RLS) is complicated by a lack of controlled trial data, limited availability of HIV-2-active antiretroviral drugs, and inadequate access to drug res...

    Dana N. Raugi, Khardiata Diallo, Mouhamadou Baïla Diallo, Dominique Faye… in Trials (2021)

    Download PDF (1119 KB) View Article

  2. Article

    Open Access

    In vitro activity of dolutegravir against wild-type and integrase inhibitor-resistant HIV-2

    Dolutegravir recently became the third integrase strand transfer inhibitor (INSTI) approved for use in HIV-1–infected individuals. In contrast to the extensive dataset for HIV-1, in vitro studies and clinical ...

    Robert A Smith, Dana N Raugi, Charlotte Pan, Papa Salif Sow, Moussa Seydi… in Retrovirology (2015)

    Download PDF (979 KB) View Article

  3. No Access

    Article

    Genetic impact of vaccination on breakthrough HIV-1 sequences from the STEP trial

    The STEP HIV-1 vaccine trial failed to protect volunteers from infection, but whether vaccine-driven immune responses affected the profile of viral variants in infected individuals was unknown. By analyzing nu...

    Morgane Rolland, Sodsai Tovanabutra, Allan C deCamp, Nicole Frahm… in Nature Medicine (2011)